Response
The CD150 high compartment is not the exclusive reservoir of LT-HSCs within the bone marrow Kiel et al respond to our recent article 1 demonstrating that subsets of functional long-term repopulating hematopoietic stem cells (LT-HSCs) can be distinguished based on Hoechst dye exclusion (side population, SP) coupled with CD150 (signaling lymphocytic activation molecule family member 1, SlamF1) staining, with both CD150 ϩ and CD150 Ϫ populations containing substantive numbers of LT-HSCs. We appreciate the opportunity to address these concerns.
In our report, we did not dispute (and, indeed, functionally corroborated) the existence of LT-HSCs defined by CD150 ϩ CD48 Ϫ CD41 Ϫ . In Figure 1 of our article, 1 our objective was to underscore the necessity of stringent CD150 ϩ gating for optimal HSC enrichment. Most investigators use isotype controls to identify "positive" cells. We showed in Figure 1B that such a strategy with the SLAM-family markers would result in populations with relatively low HSC purity, and noted that slight changes in gating lead to quite disparate outcomes. For this very reason, we entreated users desiring superior HSC enrichment to use the stringent CD150 high gates shown in Figure 1C (similar to Figure 4A in Kiel et al 2 ), or to include canonical markers to assist HSC identification (as in Morrison's recent work 3 ). We proposed a CD150 "high" designation for SLAM-identified HSCs to emphasize this point.
Kiel et al also suggest that the observed LT-HSC activity in the CD150 Ϫ c-Kit ϩ Lin Ϫ Sca-1 ϩ (KLS) side population (SP KLS ) might be attributable to contamination by rare CD150 ϩ cells. To minimize this possibility, we set exceptionally stringent gates for defining CD150 Ϫ and CD150 ϩ cells ( Figure 4A 1 ) , making cross-contamination unlikely. We also reanalyzed sorted samples, to verify purity, showing that fewer than 1 in 100 CD150 Ϫ SP KLS cells could be CD150 high contaminants ( Figure 4A 1 ).
While CD150 Ϫ SP KLS cells do show a lower contribution to blood chimerism, this deficit is mild ( Figure 4B 1 ). Thus, to attribute the HSC activity of this compartment to a stray CD150 high cell would assume extraordinary potency, as this cell would have to perform comparably to 100 of its CD150 ϩ counterparts, a result which seems implausible, particularly since 100% of our animals (14/14) that received transplants of 100 CD150 Ϫ SP KSL cells in independent experiments demonstrated full multilineage reconstitution. The 2 studies 4,5 that Kiel et al suggest we overlooked did not investigate whether CD150 Ϫ bone marrow fractions contained reconstituting activity, but do confirm that SlamF1 transcripts are enriched in HSCs (as do our data 6 ).
We agree with Kiel et al that limiting dilution experiments are of value to precisely assess the HSC activity of a given marrow compartment. However, the robust reconstituting ability of only 100 CD150 Ϫ SP KLS across all recipients strongly supports substantive LT-HSC activity in the CD150 Ϫ compartment. Moreover, previous studies on the SP KLS population, included as a benchmark in our current study, demonstrated that approximately 35% of singly transplanted SP KLS cells yielded long-term multilineage reconstitution in transplantation assays, 7 a number comparable with the approximately 40% to 45% of single SLAM cells. 2 Given that single SP KLS cells were transplanted without knowledge of their CD150 status, and coupled with our demonstration that the lower SP is only approximately 50% positive for CD150 in young mice ( Figure 2B 1 ) , it stands to reason that the proportion of HSCs in the CD150 Ϫ SP KLS fraction is not trivial.
As we gain more insight into HSCs, it becomes clear that, like many biologic processes, HSC function is more complex than originally suspected. Recent work points away from a concept of LT-HSCs as a functionally homogenous population toward an emerging picture of HSCs in multiple states, 8 including greater proliferation than previously thought. 9 We feel our data help open new avenues, generating novel hypotheses with broad explanatory power. As we discuss more fully, 1 CD150 differences could suggest alternate HSC niches, and help explain distinct differentiation patterns of single HSCs. 8 Future work may more fully illuminate the enigmatic HSC. To the editor:
Dasatinib suppresses in vitro natural killer cell cytotoxicity
The recent publication by Schade et al 1 demonstrated that the Src/Abl kinase inhibitor dasatinib (Sprycel), used for the treatment of chronic myeloid leukemia, 2 inhibits the function of T cells in vitro and in vivo. Dasatinib inhibition of the Src-family kinase LCK, which is critical for T-cell receptor (TCR) signaling, was proposed as the mechanism for inhibited T-cell function. To extend our understanding of the potential impact of dasatinib on the immune system we have evaluated the effects of dasatinib on natural killer (NK) cells. NK cells were isolated from normal blood through negative immunomagnetic isolation (Miltenyi Biotec, Auburn, CA) after density centrifugation to isolate peripheral blood mononuclear cells (PBMCs). Normal blood was collected with informed consent according to the Declaration of Helsinki and experiments were approved by the Human Ethics Committee, Royal Adelaide Hospital (Adelaide, Australia). NK cell activity was assessed by measuring cytotoxicity against the K562 and Jurkat cell lines. Cytotoxicity was assessed by flow cytometry using a modification of the method described in Hoppner et al. 3 NK cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen, Carlsbad, CA) as described previously 4 and cultured at a 10:1 ratio with target cells in the presence of 0 to 100 nM dasatinib. After 3 hours the proportion of apoptotic and dead cells in the CFSE-negative target population was determined by annexin V (BD Biosciences, San Jose, CA) and 7-amino-actinomycin D (7AAD; Invitrogen) staining and cell counts were also performed. As shown in Figure 1 , dasatinib reduced NK cell cytotoxicity in a dose dependent manner with maximal effect achieved at approximately 25 nM. While potently inhibited, NK function was not completely blocked by dasatinib with approximately 10% cytotoxicity against target cells observed at 100 nM. The effect of dasatinib on NK function was largely reversible as washing NK cells to remove dasatinib after a 3-hour incubation with 25 nM dasatinib restored approximately 90% cytotoxicity against K562 cells compared with untreated control cells (data not shown). The viability of both cell lines was not affected by dasatinib alone during the short drug exposure in these experiments (Figure 1) .
Src-family kinases play an important role coupling receptor activation to intracellular signaling in NK cells. Unlike T-cells where LCK plays a critical role in TCR signaling, there is greater redundancy in NK cell signaling pathways and a number of Src-family kinases including LCK, Fyn, and Src are involved. [5] [6] [7] Thus, the broad Src-kinase inhibitory activity of dasatinib is likely to be necessary for inhibition of NK cytotoxicity. Additionally the Src-kinase inhibitor (PP2) has previously been shown to significantly reduce NK cell cytotoxicity. 8 As NK cells provide a first line of defense against viruses and provide surveillance against tumors, 
